Clinical Trials Sponsored by Anshan Tumor Hospital

Total 1089 results

Liaoning Tumor Hospital & Institute
Huludao central hospital; Anshan Tumor Hospital; Chaoyang Central Hospital; Fukuang...

Not yet recruiting

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Breast Neoplasm Female
Anyang Tumor Hospital

Unknown

Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma

Esophagogastric Junction Cancer

China
Hebei Tumor Hospital

Unknown

Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer

Lung Cancer

China
Hebei Tumor Hospital

Unknown

Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

Self Efficacy

China
Anyang Tumor Hospital

Recruiting

Anlotinib for Esophageal Cancer (AFEC)

Esophageal Cancer

China
Hebei Tumor Hospital

Unknown

A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

Gastric Cancer

China
Hebei Tumor Hospital

Unknown

Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University
Wuhan University; Tongji Hospital; Hunan Province Tumor Hospital; Second Affiliated... and other collaborators

Recruiting

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma (IMRT)

Nasopharyngeal Carcinoma

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (Apple)

Efficacy
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Advanced Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Recruiting

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (PACIFIC15)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Lung Adenocarcinoma | ALK Gene Mutation | Immunotherapy

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Breast Cancer
Liaoning Tumor Hospital & Institute

Not yet recruiting

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (POSEIDON)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Completed

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Hunan Province Tumor Hospital

Completed

Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Completed

To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers

Carcinoma, Non-small Cell Lung

China
Hunan Province Tumor Hospital

Completed

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Severe Adverse Events Biomarkers Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type (Esporta)

Uncommon Pathological Types of Lung Cancer

China
Liaoning Tumor Hospital & Institute

Unknown

Irinotecan for Advanced and Metastatic Breast Cancer

Breast Cancer

China
Hunan Province Tumor Hospital

Completed

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

China
Jilin Provincial Tumor Hospital

Unknown

Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma

Advanced Lung Squamous Cell Carcinoma

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Advanced Breast Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small Cell Lung | EGFR Gene Mutation

China
Hunan Province Tumor Hospital

Completed

Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC (CLASSIC5)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases (OMESIA)

Non Small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Completed

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

Chemotherapy-induced Thrombocytopenia

China

3

Subscribe